Home > Boards > US OTC > Biotechs >

Regen BioPharma Inc. (RGBP)

Add RGBP Price Alert      Hide Sticky   Hide Intro
Moderator: gotinearly, Bigfootbud, Carter, LoveAndLight, cash4, Skiluc
Search This Board: 
Last Post: 12/6/2021 11:20:17 PM - Followers: 1122 - Board type: Free - Posts Today: 0


Regen BioPharma 
Followers: 388 Since 10/10/19

 0.000x  Ticker Symbol: RGBP 
Last iBox update 08/09/2020 4PM by CrazyKar123



Cell Therapy Technologies Market – Global Industry Insights and Forecast year 2018-2025
SAN DIEGO , Aug. 15, 2019 /PRNewswire/ -- Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP),
Regen BioPharma Inc. Files Immuno-Oncology Patent Application on Synergy of Cannabidiol With NR2F6 Modulation

All other Regen BioPharma News


Regen BioPharma, Inc. 4700 Spring Street, Suite 304
La Mesa, CA 91942 U.S.A.

Telephone: (619) 702-1404
Fax: (619) 330-2328

Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP)  focused on the immunology and immunotherapy space. The Company plans to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is advancing small molecule therapies for treating cancer and autoimmune disorders by modulating the Checkpoint NR2F6.  The company also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate).


Product Pipeline | Regen BioPharma, Inc.

Small Molecules Targeting Cancer and Autoimmunity

Regen has identified and filed patents on small molecules that activate and inhibit a novel gene (NR2F6) which controls how the immune system reacts to cancer cells and to inflammatory responses.
  • Objective is to identify small molecules that can activate and inhibit NR2F6
    ?Currently in pre-clinical development 
    Initial indications (inhibitor): bladder cancer, myelodysplastic syndrome, lung cancer
    Initial indications (activator): rheumatoid arthritis, inflammatory bowel disease, psoriasis
    Additional indications include solid tumors, acute leukemia and GVHD


Aplastic Anemia Stem Cell Therapy – HemaXellerate – IND #15376 CLEARED TO PROCEED TO PHASE I / II CLINICAL TRIALS
HemaXellerate is a personalized cellular therapeutic product designed to stimulate blood production in patients whose bone marrow is not properly functioning.
  • Fat stem cell based product to treat bone marrow that has been damaged
    Bone marrow damage occurs from radiation, chemo, or chronic conditions
    HemaXellerate uses patient’s own fat as source of endothelial cells to heal damaged bone marrow 
    ?United States Food and Drug Administration Investigational New Drug Application cleared (IND #15376)



Breast Cancer – dCellVax - IND #16200
CellVax is a dendritic cell based immunotherapy that stimulates the patient’s immune system through a process called “gene silencing.”
  • 10 advanced breast cancer patients
    Efficacy endpoints at 6 and 12 months
    Establishment of safety will allow for rapid expansion of patient numbers 
    Currently addressing FDA questions with Dr. Santosh Kesari, head of UCSD Neuro-Oncology program 



Myelodysplastic Syndrome Gene Silencing – DiffronC
DiffronC is a novel form of therapy called differentiation therapy that is expected to have much milder toxicity than chemotherapy. The mechanism of action is to correct the specific genes that prevent the myelodysplastic syndrome stem cell from producing mature blood cells.
  • siRNA silencing of our newly discovered cancer stem cell target gene
    Silencing using DiffronC induces differentiation of cancer cells 
    Initial indication is treatment of myelodysplastic syndrome 
    Other indications include solid tumors and acute leukemia


Telomeres & Genomic Integrity

Stem cells and cancer cells have found ways of maintaining their telomeres in a state that prevents senescence. Our research in to the cancer stem cell has given us a molecular pathway that can be manipulated to expand stem cells and maintain telomeres.
  • Telomeres are protective structures at the ends of chromosomes that enable cell divisions
    Telomere attrition is involved in aging, cancer and genetic mutations 
    We are developing drugs that modulate telomere maintenance 
    In pre-clinical development for indications of solid cancers and acute leukemia

Image result for cbd


Regen BioPharma, Inc. Examines Combining Cannabidiol (CBD) With Its Lead NR2F6 Agonist To Treat for Inflammatory Bowel Disease


SAN DIEGO, January 8, 2019 /PRNewswire/ --   https://www.otcmarkets.com/stock/RGBP/news/Regen-BioPharma-Inc-Examines-Combining-Cannabidiol-CBD-With-Its-Lead-NR2F6-Agonist-To-Treat-for-Inflammatory-Bowel-Disea?id=214869

Regen BioPharma, Inc. (OTCQB: RGBP) and (OTCQB: RGBPP), reports its researchers have determined that combining its lead NR2F6 small molecule agonist with Cannabidiol (CBD) may provide a dynamic therapy for treating inflammatory bowel disease (IBD). Currently, there are a number of pre-clinical and clinical studies being conducted by other companies regarding pain management that suggest potential benefits of CBD. Regen believes that CBD may augment the Company's small molecule therapies for autoimmune disorders, in this case specifically IBD.

IBD is a disease caused by persistent and chronic inflammation of the gastrointestinal tract and is a term that refers to both ulcerative colitis and Crohn's disease. Current treatments include non-specific immune suppressors such as steroids as well as newer drugs recently approved by the FDA. The IBD market size is estimated at $6.7 billion global and projected to be $7.6 billion by 2023.There are currently no non-steroidal therapies  available to IBD sufferers.

"Our ex-vivo studies with RG-NAH005 (Regen's small molecule agonist) support moving the drug into animal studies where we can measure the effect of the drug on different diseases," says Harry Lander, Ph.D., President and Chief Scientific Officer of Regen.  "We believe incorporating CBD in our studies will allow us to potentially strengthen positive outcomes for patients."

The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 small molecule program at Regen aims to identify antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a patient's own immune system as well as identifying agonists which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity and chronic inflammation.

"We are pleased that RG-NAH005 has shown a safety profile that allows us to move it into animal studies," says David Koos, Ph.D., Chairman & CEO of both Regen BioPharma, Inc. and Zander Therapeutics, Inc. "We are enthusiastic that combining CBD with our small molecule agonist will potentially make our small molecule therapy for IBD more dynamic is its approach to treating this disease."



Always research for yourself BEFORE you buy in the OTC !!!!

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
RGBP News: Current Report Filing (8-k) 11/12/2021 05:01:10 AM
RGBP News: WPUR 29,000% 52-Week Gain Proves Water Can Be As Valuable As Gold 11/05/2021 06:29:13 AM
RGBP News: Current Report Filing (8-k) 11/05/2021 06:01:56 AM
RGBP News: Current Report Filing (8-k) 11/04/2021 02:47:52 AM
RGBP News: Current Report Filing (8-k) 10/22/2021 11:46:36 AM
#97394  Sticky Note Have you seen this? Massive NR2F6 implications!!! Skiluc 11/14/21 10:10:02 AM
#95936  Sticky Note Today's 8-K is Outstanding NEWS!!! Dilution is OVER! :-) LoveAndLight 11/05/21 11:06:17 AM
#82070  Sticky Note Regen BioPharma Inc (OTCMKTS: RGBP) Mega Runner as cash4 08/21/21 07:33:47 PM
#41420  Sticky Note RGBP/Zander patents... gotinearly 03/29/21 09:43:29 AM
#99748   Wee doggie joe botts 12/06/21 11:20:17 PM
#99747   There are a few ways if not many,to raja48185 12/06/21 11:05:20 PM
#99746   VOLUME SPEAKS VOLUMES and the RGBP’s August history 29YEARINVESTOR 12/06/21 11:05:16 PM
#99745   Vague losses are still losses! Down 80% pumper_stumper 12/06/21 10:56:34 PM
#99744   That was Hogan's Heroes it_happens 12/06/21 10:41:50 PM
#99743   It’s hard for some to pick a exact 29YEARINVESTOR 12/06/21 10:32:59 PM
#99740   Oh ok , wow, shazam joe botts 12/06/21 09:40:14 PM
#99739   Somebody told me there on every night certain joe botts 12/06/21 09:38:59 PM
#99738   Educate us how shares purchased over 6 cents pumper_stumper 12/06/21 09:32:14 PM
#99737   Kinda had a thing for Melody Patterson.lol. moondogaz 12/06/21 09:31:05 PM
#99736   A no brainer for those of us who Goldstrike 12/06/21 09:28:26 PM
#99735   HOWEVER. F troop was one of the best joe botts 12/06/21 09:28:14 PM
#99734   Exactly. figures your the one who corrected me.lol. moondogaz 12/06/21 09:27:16 PM
#99733   No, sergeant Schultz Hogan's heroes! joe botts 12/06/21 09:21:17 PM
#99732   I know nothing. Sgt. Schultz.. F-Troop. moondogaz 12/06/21 09:12:00 PM
#99731   Oh, quit. jonestint 12/06/21 09:05:19 PM
#99730   Tomorrow or wed.. news. $1 bet... moondogaz 12/06/21 08:58:19 PM
#99729   Well wow weeee joe botts 12/06/21 07:57:20 PM
#99726   Yep! Traders that average down on RGBP lows, 29YEARINVESTOR 12/06/21 07:47:05 PM
#99724   rgbp--->CooooooL-SLIDING_INTO_THE_BASEMENT(.015-.012)!!!!---> Sat Naam 12/06/21 06:49:13 PM
#99723   To me, any excitement is about the future SustainedByGrace 12/06/21 06:16:14 PM
#99722   Ahh, talk about the good old days of pumper_stumper 12/06/21 06:10:53 PM
#99721   Yes it was over at 8 cents twice 29YEARINVESTOR 12/06/21 05:57:22 PM
#99720   Awww ohhhh thank ya joe botts 12/06/21 04:07:29 PM
#99719   Sorry for the delayed reply. But if you raja48185 12/06/21 04:04:26 PM
#99718   Back on track! !$RGBP red in 17 out pumper_stumper 12/06/21 04:01:55 PM
#99717   5-7% a day Jaguarjacket 12/06/21 03:20:10 PM
#99716   Oh boy beginneer 12/06/21 02:56:53 PM
#99714   There's so much excitement here for a stock jonestint 12/06/21 02:48:00 PM
#99713   wow nice!! Johnnie Ringo 12/06/21 02:07:11 PM
#99712   But he has a sociology degree, which is pumper_stumper 12/06/21 02:06:53 PM
#99709   Awww OK now.... joe botts 12/06/21 01:25:44 PM
#99708   It wasn't over at 6 cents, it wasn't pumper_stumper 12/06/21 01:21:37 PM
#99707   Is the daily dump a thon art35 12/06/21 01:14:14 PM
#99704   Wow , really? Gee now..ohhh ok joe botts 12/06/21 01:05:42 PM
#99703  Restored The dude is a con artist. Huggy Bear 12/06/21 12:56:46 PM
#99702   https://docoh.com/search?q=0001589150 29YEARINVESTOR 12/06/21 12:53:01 PM
#99701   Aw Jeez.. Dr. Koots is a mealy mouthed Goldstrike 12/06/21 12:42:48 PM
#99700   You are correct sir... tryn2 12/06/21 11:53:11 AM
#99699   Good joe botts 12/06/21 11:33:58 AM
#99695   rgbp--->FAKE_BID_YANKED--->LET_THE_BASEMENT(.015-.012)_SLIDE_BEGIN!!!! Sat Naam 12/06/21 09:42:50 AM
#99694   This is what we are all waiting for, kenbe 12/06/21 08:56:26 AM
#99693   MM mischief in between news releases. They have zombywolf 12/06/21 08:32:24 AM
#99691   Nice to see you Midnightmaraude 12/05/21 11:14:30 PM
#99690   Told you... ecmoney 12/05/21 10:40:29 PM
#99689   100% agreed. Sometimes its how we wait. And Skiluc 12/05/21 10:09:34 PM
#99683   20 or 30? joe botts 12/05/21 05:40:05 PM
#99682   That’s great but the stock keeps going down noode12 12/05/21 05:36:01 PM
#99681   Chairman and CEO David Koos noted, "Checkpoint inhibitors loophole lawyer 12/05/21 04:47:44 PM
#99680   https://biosignaling.biomedcentral.com/articles/10.1186/s12964-019-0454-z If vi loophole lawyer 12/05/21 04:33:46 PM
Consent Preferences